ADHD Medication Shortage UK 2026 - What It Is, Why It Happens, and What To Do

Since October 2023, every licensed ADHD medication in the UK has been affected at some point, although not all at the same time. The pattern has been rolling: one medication or dose comes back into supply, another goes out.

Lisdexamfetamine (Elvanse, Elvanse Adult, Aduvanz) has had the longest-running supply problems, particularly in the 30 mg, 50 mg and 70 mg strengths. This is the medication patients have most often had to switch from.

Methylphenidate modified-release preparations (Concerta XL, Xaggitin XL, Delmosart, Matoride, Xenidate) have had intermittent supply problems, with some brands more affected than others. Pharmacists have been able to source one brand when another was unavailable, though the bioavailability of different brands is not always identical.

Methylphenidate immediate-release (Ritalin, Medikinet, generic methylphenidate) has been the most reliable of the licensed products, although it has not been entirely immune to supply issues. It has often been used as an interim bridge while patients waited for their usual modified-release product to come back into stock.

Atomoxetine (Strattera, generic atomoxetine) has been less affected than the stimulants and is the licensed non-stimulant option. It is not a like-for-like substitute for stimulants and should only be switched under specialist advice.

Guanfacine (Intuniv) and dexamfetamine have also been licensed but are used less frequently in adults. Both have had spot shortages but are not always available as straightforward substitutes for the more commonly used products.

The shortage has several overlapping causes and there is no single villain. The UK pharmaceutical supply chain depends on global manufacturing, raw material availability, and forecasting that has not always kept pace with rising demand.

Demand for ADHD medication in the UK rose sharply after the pandemic, in part because of better awareness, in part because Right to Choose pathways made diagnosis more accessible, and in part because the long NHS waiting lists released a backlog of patients into Right to Choose providers. Manufacturers had not planned for the new level of demand.

Manufacturing constraints have affected several products independently. The active pharmaceutical ingredient in stimulants is a controlled substance, which means production quotas are set in advance with the UK Home Office. When demand rises faster than the quota, supply tightens even if the manufacturer is willing to make more.

Brexit-related logistics added friction to imports, increasing lead times and reducing the buffer stock that pharmacies and wholesalers used to hold. The combined effect of higher demand, tighter manufacturing, and longer logistics created the conditions for the shortage that began in 2023 and has not fully resolved.

It is worth understanding all of this not because it changes your situation as a patient, but because it sets expectations. The shortage is structural rather than a one-off, and the system is improving slowly rather than in a single rebound. Planning your prescriptions around that reality is more useful than waiting for "normal" to return.

Stock varies pharmacy by pharmacy and week by week, so a phone call to two or three local pharmacies, asking specifically whether they have your medication, your dose and your brand in stock, gives you the most accurate live picture. Many pharmacies will hold a 28-day pack for you if you can collect within a day or two.

The Specialist Pharmacy Service publishes guidance on current Medicine Supply Notifications that affect ADHD medication. The notifications include the product, the strength, the expected return-to-supply date if known, and the recommended clinical approach for prescribers and pharmacists during the shortage. Asking your prescribing clinician to refer to the current notification is reasonable and helpful.

Online pharmacies sometimes have stock when local pharmacies do not, particularly Boots Online, LloydsDirect, Echo by LloydsDirect, and Pharmacy2U. The trade-off is delivery time. If your supply is about to run out within a few days, a local pharmacy with stock is faster than an online order, even if the online pharmacy has it in the warehouse.

NHS Business Services Authority and individual ICB (Integrated Care Board) websites sometimes publish regional stock guidance, though this is less consistent. A short call to your GP practice pharmacist, where one exists, can also help because they have visibility of which products are being dispensed across the local system.

Request your repeat prescription as soon as the system allows you to, typically seven days before you run out. Earlier requests give you time to find a pharmacy with stock if your usual one cannot dispense.

Ask your GP for a paper FP10 prescription you can take to whichever pharmacy has stock, rather than a fixed electronic prescription tied to a single nominated pharmacy. The Electronic Prescription Service can be redirected to a different pharmacy, but a paper script gives you the most flexibility in a hunt week.

If your usual brand of methylphenidate modified-release is not available, ask your prescriber to add a permitted alternative brand to the prescription. The brands are not always bioequivalent, so this conversation is worth having with the prescriber rather than relying on a pharmacist substitution. Where the bioavailability differs, your usual dose may need a short re-titration.

If lisdexamfetamine is the medication in shortage and a switch becomes necessary, the most common interim bridge is short-acting methylphenidate (Ritalin or Medikinet), taken in divided doses to cover the day. This is a prescribing decision for your specialist or GP under shared care. Do not switch yourself.

Keep a small buffer if you can. Two to three days of stock in hand, banked across one or two prescription cycles, makes a real difference if your next refill runs into a supply gap. Banking takes time to build because you cannot order early, but small adjustments to collection timing help over a few months.

Document any work or study impact in writing if a shortage causes a gap. Under the Equality Act 2010 your employer or education provider has a duty to make reasonable adjustments where a disability affects you. A medication gap caused by a national shortage is a reasonable thing to ask for short-term flexibility around. Our companion guide on ADHD workplace rights covers this in more detail.

If a switch becomes necessary, it should always be under specialist or GP advice. ADHD medications are not interchangeable on a one-to-one basis. Stimulants and non-stimulants work through different mechanisms, and even within the stimulant class, lisdexamfetamine and methylphenidate work differently enough that the dose conversion is approximate, not exact.

A rough clinical guide that prescribers use, though it is not a substitute for individualised advice, is that 30 mg of lisdexamfetamine is broadly equivalent to 27 mg of long-acting methylphenidate, 50 mg of lisdexamfetamine is broadly equivalent to 54 mg of long-acting methylphenidate, and 70 mg of lisdexamfetamine is broadly equivalent to 72 mg of long-acting methylphenidate. These are starting points, not endpoints. Most patients need a short re-titration after a switch.

A switch should be followed by a check-in appointment within two to four weeks. Effects, side effects, sleep, appetite and mood are all worth tracking. If you keep a brief daily note for the first month after a switch, you will give your clinician far more useful information at the review than recall alone.

If the switch is to a non-stimulant such as atomoxetine, expect a four to six week onset of effect rather than a same-day response. This is a significant clinical change and should only be considered if no stimulant option is available, or if there is a separate clinical reason for moving to a non-stimulant.

For children and young people, the impact of a gap is often more visible at school than at home. Teachers may notice a sudden change in concentration, behaviour or self-regulation that lines up with the medication gap. Where this is happening, telling the SENCO or pastoral lead in writing creates a record and protects the young person from any sanction that might otherwise follow.

Specialist CAMHS clinicians and community paediatricians are the prescribers for most young people on ADHD medication, often under shared care with the GP. If a switch is needed, the specialist is the right route. GPs typically cannot make significant changes to a young person's ADHD prescription without specialist input.

A short note from the specialist to the school explaining the cause of the change in behaviour, and confirming that the school is not seeing a regression but an interruption in supply, often helps. Schools that understand the reason for the change tend to respond with more patience and more useful adjustments.

The Department of Health and Social Care, the MHRA and the major manufacturers have all signalled steady improvement through 2025 and into 2026, with most products returning to reliable supply across most doses. The pattern has been one of gradual normalisation rather than a single end-point. New Medicine Supply Notifications are still being issued occasionally for specific products and doses, so the system is not back to pre-2023 reliability yet.

The factors that caused the shortage are mostly being addressed. Manufacturers have invested in additional capacity, the Home Office quota system has been adjusted, demand forecasting is better than it was in 2023, and pharmacy stock buffers have rebuilt to some degree. None of that is a guarantee, but the direction of travel is positive.

Realistically, planning your medication around the assumption that the supply chain is not fully reliable - asking for repeats early, knowing two or three pharmacies that can dispense, keeping in touch with your prescriber - remains a sensible default for the rest of 2026. By the end of the year the picture should be substantially better, although a small risk of intermittent gaps is likely to persist.

My ADHD Path is built specifically for adults navigating ADHD in the UK NHS system. The tools below help with the shortage directly.

My Letter Templates include a GP letter requesting a paper FP10 prescription, a letter to a specialist requesting a brand switch with named clinical reasoning, a letter to a school explaining a young person's medication gap, and a workplace letter requesting reasonable adjustments under the Equality Act 2010 during a supply gap.

My Pro AI Chat answers situation-specific questions about the shortage. If you are mid-switch and want to talk through what to track, what to ask your prescriber, or how to plan your collection week, the chat is a useful place to do that.

My Medication Tracker (Pro) lets you log dose, time, effects, side effects and sleep. The output is a structured report you can bring to your specialist review, which is particularly valuable after a switch.

For step-by-step guidance on the wider ADHD pathway in the UK, see our companion guides on UK ADHD medications, ADHD medication side effects, and shared care agreements.